Skip to main content
OpenTrials
Completed

NCT Number: NCT04555187

Cardiovascular Risk Stratification in Covid-19

This retrospective double-cohort study seeks to:

1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Cardiovascular Risk Factor Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Oregon Health and Science University

Portland, Oregon, 97239, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age >=18y
  • available data on Covid19 test in the electronic medical record (either positive or negative)

Exclusion criteria

  • no data of Covid19 test

Treatment and study plan

Primary outcomes

  1. Number and rate of persons with cardiovascular composite outcome

    Time frame: 6 months after Covid19 test

    Number and rate of persons with composite of all-cause death, critical care utilization (ICU bed), development of a life-threatening arrhythmia (ventricular tachycardia/ventricular fibrillation or sudden cardiac arrest), acute heart failure, myocardial infarction (STEMI, NSTEMI, or silent MI), or incident stroke, whichever comes first.

Secondary outcomes

  1. Rate of all-cause death outcome

    Time frame: 6 months after covid19 test

    Rate of all-cause death outcome

  2. Rate of cardiac arrhythmia

    Time frame: 6 months after covid19 test

    Rate of any documented cardiac arrhythmia (tachy - or brady- arrhythmia)

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Acronym: CaVaR-Co19

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Sep 18, 2020
Registry last updated
Nov 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.